Delisting riskPopularity #3,534
BIAF · NASDAQ · Medical - Diagnostics & Research

bioAffinity Technologies (BIAF)

Runs a pathology laboratory and sells a sputum-based lung-cancer assessment test.

$8.66
After hours+0.07 (+0.85%)
At close$8.59(+11.56%)

Something off on this page? Send us feedback.

Next report
Nov 18, 26
estimated · in 57 days
EPS estimate
−$31.50
Revenue estimate
$1.9M
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$6.31−$4.80−$5.10−$4.74−$1.11−$0.81−$9.60Pending
Estimate−$4.20−$4.80−$3.00−$2.70−$2.70−$2.40−$31.50−$31.50
Surprise−50.2%0.0%−70.0%−75.6%+58.9%+66.3%+69.5%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$2.2M$1.9M$1.3M$1.4M$1.6M$1.4M$1.5MPending
Estimate$2.4M$2.1M$1.5M$1.4M$1.6M$1.5M$1.7M$1.9M
Surprise−8.9%−12.1%−15.7%+2.5%+2.5%−8.9%−11.2%

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Dec 2026−$27.00
Nov 2026−$31.50
Aug 2026−$31.50−$9.60+69.5%
May 2026−$2.40−$0.81+66.3%
Mar 2026−$2.70−$1.11+58.9%
Nov 2025−$2.70−$4.74−75.6%
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Apr 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
Mar 2022
Dec 2021
Sep 2021
Jun 2021
Mar 2021
Dec 2020

The latest year is open to everyone — the 19 quarters behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Dec 2026−$27.00$2.2M
Nov 18, 2026−$31.50$1.9M
Aug 7, 2026−$31.50−$9.60+69.5%$1.7M$1.5M−11.2%−3.8%
May 8, 2026−$2.40−$0.81+66.3%$1.5M$1.4M−8.9%−4.3%
Mar 13, 2026−$2.70−$1.11+58.9%$1.6M$1.6M+2.5%−9.9%
Nov 14, 2025−$2.70−$4.74−75.6%$1.4M$1.4M+2.5%−14.1%
Aug 14, 2025
May 15, 2025
Mar 31, 2025
Nov 14, 2024
Aug 14, 2024
May 15, 2024
Apr 1, 2024
Nov 14, 2023
Aug 14, 2023
May 15, 2023
Mar 31, 2023
Nov 14, 2022
Aug 18, 2022
Mar 31, 2022
Dec 31, 2021
Sep 30, 2021
Jun 30, 2021
Mar 31, 2021
Dec 31, 2020

The latest year is open to everyone — the 19 quarters behind it read with an account.